BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 16111664)

  • 1. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform.
    Jaschke B; Michaelis C; Milz S; Vogeser M; Mund T; Hengst L; Kastrati A; Schömig A; Wessely R
    Cardiovasc Res; 2005 Dec; 68(3):483-92. PubMed ID: 16111664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
    Jaschke B; Milz S; Vogeser M; Michaelis C; Vorpahl M; Schömig A; Kastrati A; Wessely R
    FASEB J; 2004 Aug; 18(11):1285-7. PubMed ID: 15180955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery.
    Wessely R; Blaich B; Belaiba RS; Merl S; Görlach A; Kastrati A; Schömig A
    Thromb Haemost; 2007 Jun; 97(6):1003-12. PubMed ID: 17549304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries.
    Parry TJ; Brosius R; Thyagarajan R; Carter D; Argentieri D; Falotico R; Siekierka J
    Eur J Pharmacol; 2005 Nov; 524(1-3):19-29. PubMed ID: 16271360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet-derived growth factor receptor antagonist STI571 (imatinib mesylate) inhibits human vascular smooth muscle proliferation and migration in vitro but not in vivo.
    Hacker TA; Griffin MO; Guttormsen B; Stoker S; Wolff MR
    J Invasive Cardiol; 2007 Jun; 19(6):269-74. PubMed ID: 17541129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of cytochalasin D-eluting stents on intimal hyperplasia in a porcine coronary artery model.
    Salu KJ; Bosmans JM; Huang Y; Hendriks M; Verhoeven M; Levels A; Cooper S; De Scheerder IK; Vrints CJ; Bult H
    Cardiovasc Res; 2006 Feb; 69(2):536-44. PubMed ID: 16386237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arsenic trioxide eluting stent reduces neointima formation in a rabbit iliac artery injury model.
    Yang W; Ge J; Liu H; Zhao K; Liu X; Qu X; Li W; Huang Y; Sun A; Zou Y
    Cardiovasc Res; 2006 Dec; 72(3):483-93. PubMed ID: 17020754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells.
    Blindt R; Vogt F; Astafieva I; Fach C; Hristov M; Krott N; Seitz B; Kapurniotu A; Kwok C; Dewor M; Bosserhoff AK; Bernhagen J; Hanrath P; Hoffmann R; Weber C
    J Am Coll Cardiol; 2006 May; 47(9):1786-95. PubMed ID: 16682302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A perlecan-inducing compound significantly inhibits smooth muscle cell function and in-stent intimal hyperplasia: novel insights into the diverse biological effects of perlecan.
    Segev A; Nili N; Osherov AB; Qiang B; Wong AJ; Pillarisetti S; Strauss BH
    EuroIntervention; 2010 May; 6(1):134-40. PubMed ID: 20542809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries.
    Banai S; Gertz SD; Gavish L; Chorny M; Perez LS; Lazarovichi G; Ianculuvich M; Hoffmann M; Orlowski M; Golomb G; Levitzki A
    Cardiovasc Res; 2004 Oct; 64(1):165-71. PubMed ID: 15364624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are impaired endothelial progenitor cells involved in the processes of late in-stent thrombosis and re-endothelialization of drug-eluting stents?
    Zhao FH; Chen YD; Jin ZN; Lu SZ
    Med Hypotheses; 2008; 70(3):512-4. PubMed ID: 17764856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells.
    Clever YP; Cremers B; Krauss B; Böhm M; Speck U; Laufs U; Scheller B
    EuroIntervention; 2011 May; 7 Suppl K():K32-42. PubMed ID: 22027725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valproic acid inhibits proliferation of human coronary vascular cells (SI/MPL-ratio: 0.5): a novel candidate for systemic and local therapy of postinterventional restenosis.
    Voisard R; Krebs R; Baur R; Hombach V
    Coron Artery Dis; 2010 Aug; 21(5):286-91. PubMed ID: 20508518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of combined treatment with angiotensin II type 1 receptor blocker and statin on stent restenosis.
    Yoshikawa M; Nakamura K; Nagase S; Sakuragi S; Kusano KF; Matsubara H; Ohe T
    J Cardiovasc Pharmacol; 2009 Feb; 53(2):179-86. PubMed ID: 19188828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival of endothelial cells in vitro on Paclitaxel-loaded coronary stents.
    Prasad CK; Resmi KR; Krishnan LK; Vaishnav R
    J Biomater Appl; 2005 Apr; 19(4):271-86. PubMed ID: 15788425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: a potential treatment strategy for drug-eluting stents.
    Camici GG; Steffel J; Akhmedov A; Schafer N; Baldinger J; Schulz U; Shojaati K; Matter CM; Yang Z; Lüscher TF; Tanner FC
    Circulation; 2006 Oct; 114(14):1512-21. PubMed ID: 17000906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of stem cell mobilization by granulocyte-colony stimulating factor on neointimal hyperplasia and endothelial healing after vascular injury with bare-metal versus paclitaxel-eluting stents.
    Cho HJ; Kim TY; Cho HJ; Park KW; Zhang SY; Kim JH; Kim SH; Hahn JY; Kang HJ; Park YB; Kim HS
    J Am Coll Cardiol; 2006 Jul; 48(2):366-74. PubMed ID: 16843188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating.
    Wessely R; Hausleiter J; Michaelis C; Jaschke B; Vogeser M; Milz S; Behnisch B; Schratzenstaller T; Renke-Gluszko M; Stöver M; Wintermantel E; Kastrati A; Schömig A
    Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):748-53. PubMed ID: 15681298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks.
    Garcia-Touchard A; Burke SE; Toner JL; Cromack K; Schwartz RS
    Eur Heart J; 2006 Apr; 27(8):988-93. PubMed ID: 16449248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local delivery of anti-monocyte chemoattractant protein-1 by gene-eluting stents attenuates in-stent stenosis in rabbits and monkeys.
    Egashira K; Nakano K; Ohtani K; Funakoshi K; Zhao G; Ihara Y; Koga J; Kimura S; Tominaga R; Sunagawa K
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2563-8. PubMed ID: 17885211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.